Calcitriol for Congenital Osteopetrosis

Bruce R Blazar, Michael D. Fallon, Steven L. Teitelbaum, Norma K.C. Ramsay, David M. Brown, L. Lyndon Key, Constantine S. Anast

Research output: Contribution to journalLetterpeer-review

10 Scopus citations


To the Editor: Key et al. (Feb. 16 issue)1 describe an infant with malignant osteopetrosis who had a small clinical response to highdose calcitriol (32 μg per day). A morphologic and functional change in osteoclasts was noted. We have administered high-dose calcitriol (24 μg per day) to two infants with malignant osteopetrosis. The first presented at the age of two months with mild frontal bossing, cranial-nerve dysfunction, massive hepatosplenomegaly, pallor, and developmental delay. Biochemical aberrations before therapy included elevated serum levels of parathyroid hormone, acid phosphatase, and 1,25-dihydroxyvitamin D and decreased levels of serum calcium and phosphorus. The second infant,.

Original languageEnglish (US)
Pages (from-to)55
Number of pages1
JournalNew England Journal of Medicine
Issue number1
StatePublished - Jul 5 1984


Dive into the research topics of 'Calcitriol for Congenital Osteopetrosis'. Together they form a unique fingerprint.

Cite this